0000000000535304

AUTHOR

Aurélie Herry

showing 3 related works from this author

Epidemiology of Mantle Cell Lymphoma: A Population-Based Study in France

2011

Abstract Abstract 5222 Introduction: Mantle cell lymphoma (MCL) is an aggressive and rare B-cell lymphoma entity representing around 5–8% of non-Hodgkin's lymphomas in adults. To our knowledge no data is available on the epidemiology of MCL in France. We aimed to describe incidence, survival and main clinical characteristics of MCL in a French population. Methods: Patients diagnosed with MCL were identified in three administrative areas covered by an haematological malignancies registry: the Côte d'Or (from 1988 to 2008), the Basse-Normandie (from 1997 to 2006) and the Gironde (from 2002 to 2006). Main clinical features and management characteristics were collected. World age-standardised …

education.field_of_studyPediatricsmedicine.medical_specialtyRelative survivalbusiness.industryIncidence (epidemiology)ImmunologyPopulationCell BiologyHematologymedicine.diseaseBiochemistryLymphomaInternational Prognostic IndexEpidemiologymedicineMantle cell lymphomaRituximabeducationbusinessmedicine.drugBlood
researchProduct

Trends in excess mortality in follicular lymphoma at a population level

2015

Background Since the 1990s and since the development of humanised monoclonal antibodies in 1998, the treatment of non-Hodgkin lymphoma has undergone profound changes. Follicular lymphoma (FL) was the first to benefit from this treatment, and several clinical trials have shown a significant improvement in overall survival, but little information is available at a population level. Objective Our objective was to estimate changes in FL-specific mortality at a population level, with an appropriate methodology. Methods Two French retrospective population-based studies on FL were conducted, one from 1995 to 2004, in 1477 patients, and one from 1995 to 2010, in 451 patients. Trends in excess morta…

AdultMalemedicine.medical_specialtyAdolescentPopulation level[SDV]Life Sciences [q-bio]PopulationFollicular lymphomaHistory 21st CenturyYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineIn patientRegistriesAge of OnsetStage (cooking)educationLymphoma FollicularAgedNeoplasm StagingRetrospective StudiesAged 80 and overExcess mortalityeducation.field_of_studybusiness.industryHematologyGeneral MedicineHistory 20th CenturyMiddle Agedmedicine.disease3. Good healthLymphomaClinical trialPopulation Surveillance030220 oncology & carcinogenesisImmunologyFemaleFrancebusiness030215 immunology
researchProduct

Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.

2014

The treatment of chronic myeloid leukemia (CML) has seen several major advances over the past 30 years, notably with the introduction of interferon followed by Bcr-Abl tyrosine kinase inhibitors. We analyzed trends in the incidence of CML and patient survival in France. All cases recorded in five population-based registries between 1980 and 2009 were included. European (ESR) and world (WSR) standardized incidence rates as well as relative survival (RS) rates were estimated. We analyzed data for 781 patients (9863/3: 13.6%; 9875/3: 82.2%; 9876/3: 4.2%). ESR was 1.02 [95% confidence interval (CI) = 0.93-1.11] and WSR was 0.81 [95% CI = 0.72-0.90]. The five RS rates among patients with Philade…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulation03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansRegistrieseducationChildSurvival analysisAgedAged 80 and overeducation.field_of_studyPhiladelphia Chromosome PositiveRelative survivalbusiness.industryIncidence (epidemiology)IncidenceInfant NewbornMyeloid leukemiaCancerInfantHematologyMiddle Agedmedicine.diseaseSurvival AnalysisConfidence interval3. Good healthOncology030220 oncology & carcinogenesisChild PreschoolPopulation SurveillanceImmunologyDisease ProgressionFemaleFrancebusiness030215 immunologyFollow-Up StudiesLeukemialymphoma
researchProduct